In this latest commentary, Dr. David Johnson spotlights six breakthrough studies poised to influence GI practice. A serum-based test shows promising accuracy for early pancreatic cancer, potentially outperforming CA19-9. New data reveals unexpectedly high adenoma formation after immune-checkpoint-inhibitor colitis — raising questions about how soon to re-scope these patients. Another study shows early biologic use may sharply reduce rehospitalization for ICI-associated colitis.
Add A Comment